SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ranbaxy Laboratories surges on getting US FDA nod for Plendil generic

18 Dec 2013 Evaluate

Ranbaxy Laboratories is currently trading at Rs. 443.70, up by 3.75 points or 0.85 % from its previous closing of Rs. 439.95 on the BSE.

The scrip opened at Rs. 442.00 and has touched a high and low of Rs. 446.80 and Rs. 438.50 respectively. So far 73253 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 525.00 on 03-Jan-2013 and a 52 week low of Rs. 253.95 on 02-Aug-2013.

Last one week high and low of the scrip stood at Rs. 442.95 and Rs. 416.10 respectively. The current market cap of the company is Rs. 18642.52 crore.

The promoters holding in the company stood at 63.51 % while Institutions and Non-Institutions held 19.46 % and 14.29 % respectively.

Ranbaxy Laboratories has reportedly received US Food and Drug Administration (US FDA) approval for a particular drug called Plendil generic. The drug is used for hypertension. The company was expected to be the authorised generic for this particular drug, but it is already genericised and there are already 6-7 players in this market for this particular drug.

For Ranbaxy this is the first approval that they have received from the USFDA after two years, after the Lipitor generic received approval.

Ranbaxy Laboratories, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

 

Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×